The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
Zacks.com on MSN6h
EXEL Tops Q4 Earnings and Sales, Cabometyx Label Expansion in FocusExelixis, Inc. EXEL reported better-than-expected fourth-quarter results. EXEL recorded earnings of 55 cents per share, which beat the Zacks Consensus Estimate of 51 cents. The company registered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback